Congenital Cardiac Anesthesia Society
A Section of the the Society for Pediatric Anesthesia

Congenital Cardiac Anesthesia Society

  • Member Login
  • Forgot Password?
  • Join
  • Home
  • About
    • Mission Statement
    • Bylaws
    • Board of Directors
    • History
    • Past Presidents
    • Charter Members
    • CCAS Lifetime Achievement Award
    • Mailing List Rental
    • Contact Us
  • Partners
    • SPA
    • SPPM
    • PALC
    • PCICS
    • AmSECT
    • SMACT
    • CHA
    • CCAN
  • Committees
    • CCAS Committees
      • Pediatric Cardiac Anesthesiology Program Director’s Group (PCAPD) Committee
      • Communications Committee
      • CCAS-STS Database Committee
      • Education Committee
      • Global Health Committee
      • Membership Committee
      • Quality and Safety Committee
      • Research Committee
    • CCAS Special Interest Groups
      • Adult Congenital Heart Disease Special Interest Group (SIG)
      • ERAS Special Interest Group (SIG)
      • Hemostasis Special Interest Group (SIG)
      • Latin America Special Interest Group (SIG)
      • Pulmonary Hypertension Special Interest Group (SIG)
      • Trainee Special Interest Group (SIG)
  • Membership
    • Benefits of Membership
    • CCAS Member App
    • Membership Categories
    • Join CCAS
      • Online Application
      • Printable Application
    • Renew Your Dues
    • Sponsor a Member
    • Get Involved
  • Meetings
    • Upcoming Meetings
    • Past Meetings
    • Other Meetings
    • Exhibit Information
  • Education
    • CCAS Virtual Visiting Professor Program
    • CCAS Webinar Series
      • CCAS Webinar Series – Recordings
    • CCAS COVID 19 Webinar
    • ACHD-SIG Anesthesia Rounds
    • Lecture Series
    • Echo Tutorial
    • Archived Questions
    • Poll of the Month Archives
    • Review Articles
      • CCAS-CHiP Network Journal Watch Collaboration
      • SCVA Articles
    • Journals of Interest
    • Books of Interest
    • Educational Links
  • Resources
    • CCAS Position Statements
    • CCAS Committee Resources
    • CCAS Special Interest Group (SIG) Resources
    • CCAS Cognitive Aids
    • Newsletters
    • Research Resources
    • Mission Trips
    • Societies
    • Job Opportunities
  • Research
    • Research Committee
    • CCAS 2025 Meeting Scholarship for Students and Residents
    • Research Network & Collaborative Opportunities
    • Research Resources
    • Dolly D. Hansen, MD Research Award
    • New for 2026! CCAS QI/Education Award
    • Podcast Series for Aspiring CCAS Researchers
    • Highlight on a CCAS Researcher
    • Call for Surveys
    • STS-CCAS Database
    • Donate to the Dolly Hansen Fund
  • Trainees
    • Introduction to Pediatric Cardiac Anesthesiology
    • Trainee Lecture Series
    • Advanced Training
    • Pediatric Cardiac Anesthesiology Fellowship Common Goals and Objectives
    • Frequently Asked Questions
    • Pediatric Cardiac Anesthesia Education Resources
    • Coaching/Mentoring Initiative
  • Patients
    • FAQs for Cardiac Anesthesia
    • FAQs for Cardiac Anesthesia – Spanish
    • SmartTots FAQs for Parents
    • Useful Resources for Parents

Question of the Week 348

Authors: Gokul Thimmarayan, MD - Marshfield Clinic, Marshfield, WI and Destiny F Chau, MD - Arkansas Children’s Hospital/University of Arkansas for Medical Sciences, Little Rock, AR.


A 1-day-old neonate with congenital complete heart block is scheduled for a pacemaker placement. Echocardiographic findings reveal a structurally normal heart. What is the MOST COMMON cause of isolated congenital complete heart block?

Correct! Wrong!

Question of the Week 348
Congenital complete heart block (CCHB) is a rare disorder that is associated with high morbidity and mortality occurring in approximately 1:15-20,000 patients. CCHB describes atrioventricular block diagnosed in utero or during the first 27 days of life. Of the patients with CCHB, fourteen to forty-two percent of cases are associated with congenital heart disease (CHD). This may include congenitally corrected transposition of the great arteries, complete atrioventricular canal defect, and heterotaxy with left atrial isomerism. Maternal autoimmune antibody transfer is the most common cause (ninety-one percent) of CCHB in the remaining percentage of cases. Maternal factors like diabetes, medication exposure (anticonvulsants and retinoic acid), viral infections, and channelopathies are also associated with increased risk of CCHB in the offspring.


Autoimmune CCHB is a manifestation arising from neonatal lupus. Passively transferred maternal autoantibodies to the ribonuclear protein RO (SS-A) and LA (SS-B) cause neonatal lupus. Women with positive antibody titers carry approximately a two percent risk of having a baby with neonatal cardiac lupus after a prior unaffected pregnancy and have a thirteen to eighteen percent risk in subsequent pregnancies. The autoantibodies bind to the cardiac conduction tissue causing inflammation and fibrosis leading to conduction defects. The antibodies are also postulated to affect myocardial cells resulting in cardiomyopathy and endocardial fibroelastosis. Slow heart rate in the fetus with no structural anomaly of the heart and positive maternal antibody is diagnostic of autoimmune CCHB. The vast majority of infants present with third-degree or complete heart block although the presentation may vary from first- to third- degree atrioventricular block. Autoimmune CCHB has an approximate mortality rate of nineteen percent in which a majority occur in utero. Risk of fetal mortality is increased with hydrops, diagnosis of CCHB at earlier than twenty weeks of gestation, ventricular escape rate less than fifty-five beats per minute , impaired left ventricular function, myocardial inflammation, and dilated cardiomyopathy. The presence of dilated cardiomyopathy is a poor prognostic factor. Noncardiac manifestations of neonatal lupus typically self-resolve with clearance of the maternal autoantibodies over the first months of life.


Fetal echocardiography with doppler is the standard diagnostic tool in evaluating CCHB. The assessment of cardiac anatomy, heart rate and mechanical function can deduce abnormalities of electrophysiologic conduction and cardiac structure. With early diagnosis, subsequent intervention is based on the severity of the heart block along with close follow-up and monitoring with serial fetal echocardiograms. Maternal corticosteroids, intravenous immunoglobulin therapy, beta-agonist therapy, and hydroxychloroquine have been used with varying degrees of success. Once CCHB occurs, it is mostly likely irreversible, necessitating pace-maker implantation. In fact, more than two-thirds of these patients require a permanent pacemaker, the majority of which are implanted in the neonatal period.


References:


Steinberg L. Congenital heart block. Card Electrophysiol Clin. 2021; 13(4): 691-702.


Pruetz JD, Miller JC, Loeb GE, Silka MJ, Bar-Cohen Y, Chmait RH. Prenatal diagnosis and management of congenital complete heart block. Birth Defects Res. 2019; 111(8): 380-388.


Friedman DM, Duncanson LJ, Glickstein J, Buyon JP. A review of congenital heart block. Images Paediatr Cardiol 2003; 5(3): 36-48.


Izmirly PM, Chalumeau CN, Pisoni C, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent Anti-SSA/RO associated cardiac manifestation of neonatal lupus. Circulation. 2012; 126(1): 76-82.

Poll of the Month

May 2025
At your institution, do you routinely send a TEG/ROTEM during the rewarming phase of cardiopulmonary bypass?
View Results
Total Answers 130
Total Votes 130

Upcoming Meeting Information


CCAS 2026 Annual Meeting

March 12, 2026
Sheraton Denver Downtown
Denver, CO

 

 

 

 

Join CCAS
Renew
Donate
Get Involved
Upcoming
Job Postings
  • Member Login
  • Forgot Password?
2209 Dickens Road, Richmond, VA 23230 • 804-282-9780 • [email protected]
Copyright © 2025 The Congenital Cardiac Anesthesia Society | View Privacy Policy